Please login to the form below

Not currently logged in
Email:
Password:

Astellas moves into oncology

Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while also making moves into oncology

Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while also making moves to build a strong presence in oncology.

Masao Yoshida, president and CEO of Astellas, said: "Our vision at Astellas is focused on changing tomorrow for patients. The last five years have been a remarkable success, adding innovative medicines to our portfolio, which tackle key areas of unmet medical need."

Yoshida continued: "We are committed to continuing to bring our vision to life and it is very exciting for the company to begin to focus on the area of oncology."

Oncology will become Astellas Europe's sixth franchise focus in addition to its other key areas: transplantation, urology, dermatology, anti-infectives and pain management.

Its prostate cancer therapy Eligard (leuprolide acetate) is already available in selected markets and initial steps towards expanding capability have begun with the acquisition of Agensys Inc – a biotech subsidiary of Astellas that is developing a pipeline of antibodies to treat a range of solid tumour cancers.

Astellas is also in the process of bidding for OSI Pharmaceuticals, which would also expand its oncology portfolio by giving the Japanese drugmaker its first marketed cancer drug, Tarceva (erlotinib) – a lung tumour treatment.

Astellas originally placed an unsolicited bid of $3.5bn for OSI in March, but this may be increased following the recent FDA expanded approval to use Tarceva as an initial maintenance therapy against locally advanced or metastatic non-small-cell lung cancer.

Astellas has achieved robust growth since its formation from the merger of Fujisawa and Yamanouchi in 2005, expanding its reach into new therapeutic areas and achieving category leadership status in urology and transplantation in Europe.

20th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics